Global biopharmaceutical mergers and acquisitions have surged to $106 billion across 201 transactions in 2026, putting the sector on track for its strongest year since the pre-pandemic peak — a development that signals renewed confidence across the industry and intensified competition for innovative pipeline assets.
According to PitchBook data, average deal value has risen sharply to $527.3 million per transaction in 2026, up from $365 million in 2025. The acceleration is being driven by a convergence of factors: looming patent cliffs threatening billions in annual revenue for large-cap pharma, newly buoyant public markets, and an expanding universe of clinical-stage biotechs with differentiated modalities.
Pharma giants are primarily targeting bolt-on acquisitions in the $1 billion to $5 billion range. GSK’s $2.2 billion acquisition of RAPT Therapeutics has been cited as a representative deal structure. Larger deals have also emerged: Merck, Eli Lilly, and Biogen collectively committed over $12 billion across three acquisitions this year, while AI-driven drug discovery partnerships have reached new scale — highlighted by Insilico Medicine’s $2.75 billion agreement with Eli Lilly.
Oncology continues to command the largest share of deal activity, but central nervous system (CNS) and neuropsychiatric indications are attracting growing attention, reflecting the maturation of several platform technologies and an improved understanding of CNS disease biology. Metabolic disease assets — particularly those with GLP-1 or adjacent mechanisms — also remain highly sought.
For early stage biotechs, the deal environment provides clear validation signals for pipeline prioritisation and fundraising narratives. For clinical operations professionals, the wave of new M&A-fuelled development programs creates downstream demand for experienced trial execution partners — particularly in markets like Australia, where speed to first patient, regulatory efficiency, and meaningful R&D cost offsets continue to differentiate clinical development strategies.
CNBC reported that the sector is “buying stuff like it’s going out of fashion,” a characterisation that reflects both urgency and optimism after several difficult years for biotech capital markets.
